Welcome

Welcome to the McGill Artificial Pancreas Lab! Our research is focused on the development and clinical assessment of a closed-loop artificial pancreas system. 

Approach

Our multidisciplinary, bench-to-bedside approach to the physiological and clinical problems of diabetes is made possible through the application of control theory and Bayesian modeling.

Industry

We work closely with the industry to translate our research result into commercial solutions.

The Artificial Pancreas

Based on insulin pumps and glucose monitoring sensors, our lab develops an external artificial pancreas.

Multidisciplinary Approach

Our lab utilizes an interdisciplinary approach across the fields of endocrinology, nutrition, pharmacology, mathematics and control engineering.

Quantitative Methods

Quantitative approaches used in our lab include feedback control theory, mathematical modelling, system identification and Bayesian statistics.

Home

McGill Artificial Pancreas Lab
Principal Investigator: Ahmad Haidar PhD

Contact:

Duff Medical Building, Room 305
3775 University Street
Montréal, Québec
H3A 2B4
Canada                                                                                                                                                                                            

Telephone: +1 (514) 553-5500 ext. 3238
Laboratory E-mail: haidarlab.dmc [at] mcgill.ca
Principal Investigator E-mail: ahmad.haidar [at] mcgill.ca  

  

 

Diabetes Quick Facts

  • Type 1 diabetes is an autoimmune disease caused by the loss of insulin-producing cells in the pancreas.
  • Type 1 diabetes accounts for 5‑15% of 400 million people with diabetes worldwide.
  • Type 1 diabetes strikes both children and adults at any age.
  • People with type 1 diabetes must carefully balance insulin doses (either by injections multiple times a day, or continuous infusion through a pump) with eating and other activities throughout the day and night.
  • With the currently available treatment options, less than one in five patients achieve glucose targets.
Back to top